Moxifloxacin Kabi (Moxifloxacin Hydrochloride)

Moxifloxacin Hydrochloride blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By inhibiting these targets, the drug prevents bacterial DNA synthesis, leading to rapid bactericidal activity against a wide range of Gram‑positive, Gram‑negative and atypical organisms.

The specific dose and infusion rate of Moxifloxacin Kabi are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local guidelines. Healthcare professionals should follow the product label and institutional protocols.

Safety data for Moxifloxacin Kabi in pregnancy and lactation are limited. The drug should be used only if the potential benefit justifies any potential risk to the fetus or infant. Clinicians should discuss risks and alternatives with the patient before prescribing.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Moxifloxacin Kabi offers a broader spectrum against Gram‑positive and atypical pathogens compared with many earlier fluoroquinolones, and it has a higher potency for respiratory infections. Its dosing schedule often allows once‑daily administration, but safety considerations such as QT prolongation remain similar across the class.

Moxifloxacin Kabi must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Before use, allow the vial to reach room temperature if required, and inspect for particulate matter or discoloration. Follow aseptic techniques for preparation and administration.

Moxifloxacin Kabi is supplied as an injectable solution for intravenous infusion. It is administered by a qualified healthcare professional through a sterile IV line, typically over a specified period as directed by the prescribing information. Infusion equipment must be compatible with the product’s concentration.

Serious risks include tendon rupture (especially Achilles), QT interval prolongation leading to arrhythmias, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, hepatic failure, and seizures. Patients should be monitored closely for these events, and therapy should be discontinued if they occur.

Moxifloxacin Kabi is contraindicated in patients with a known hypersensitivity to moxifloxacin, other fluoroquinolones, or any component of the formulation. It should also be avoided in individuals with a history of tendon disorders related to fluoroquinolone use, uncontrolled QT prolongation, or those receiving concomitant medications that significantly increase the risk of serious cardiac events.